A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score

Summary.  Background: Prophylaxis of venous thromboembolism (VTE) in hospitalized medical patients is largely underused. We sought to assess the value of a simple risk assessment model (RAM) for the identification of patients at risk of VTE. Methods: In a prospective cohort study, 1180 consecutive patients admitted to a department of internal medicine in a 2‐year period were classified as having a high or low risk of VTE according to a predefined RAM. They were followed‐up for up to 90 days to assess the occurrence of symptomatic VTE complications. The primary study outcome was to assess the adjusted hazard ratio (HR) of VTE in high‐risk patients who had adequate in‐hospital thromboprophylaxis in comparison with those who did not, and that of VTE in the latter group in comparison with low‐risk patients. Results: Four hundred and sixty‐nine patients (39.7%) were labelled as having a high risk of thrombosis. VTE developed in four of the 186 (2.2%) who received thromboprophylaxis, and in 31 of the 283 (11.0%) who did not (HR of VTE, 0.13; 95% CI, 0.04–0.40). VTE developed also in two of the 711 (0.3%) low‐risk patients (HR of VTE in high‐risk patients without prophylaxis as compared with low‐risk patients, 32.0; 95% CI, 4.1–251.0). Bleeding occurred in three of the 186 (1.6%) high‐risk patients who had thromboprophylaxis. Conclusions: Our RAM can help discriminate between medical patients at high and low risk of VTE. The adoption of adequate thromboprophylaxis in high‐risk patients during hospitalization leads to longstanding protection against thromboembolic events with a low risk of bleeding.

[1]  P. D. de Groot,et al.  Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment , 2011, Journal of internal medicine.

[2]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[3]  S. Goldhaber,et al.  A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. , 2004, The American journal of cardiology.

[4]  T. Wakefield,et al.  Call to action to prevent venous thromboembolism. , 2009, Journal of vascular surgery.

[5]  V. Hach-Wunderle,et al.  An Evaluation of Venous Thromboembolic Risk in Acutely Ill Medical Patients Immobilized at Home: The AT-HOME Study , 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[6]  J. Paramo,et al.  Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients , 2008, Thrombosis and Haemostasis.

[7]  L. Mazzolai,et al.  Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. Francis Prophylaxis for Thromboembolism in Hospitalized Medical Patients , 2007 .

[9]  A. D’Angelo,et al.  Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants. , 1996, Annales de medecine interne.

[10]  D. Hayoz,et al.  Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement , 2005, Journal of internal medicine.

[11]  Pieter W Kamphuisen,et al.  Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. , 2006, JAMA.

[12]  I. Mackie,et al.  Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti‐phospholipid syndrome , 1997, British journal of haematology.

[13]  M. Prins,et al.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.

[14]  G. Reber,et al.  Control of Oral Anticoagulation in Patients with the Antiphospholipid Syndrome – Influence of the Lupus Anticoagulant on International Normalized Ratio , 1998, Thrombosis and Haemostasis.

[15]  P. Mannucci,et al.  Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins , 2001, British journal of haematology.

[16]  E. Oger,et al.  Venous thromboembolism (VTE) in Europe , 2007, Thrombosis and Haemostasis.

[17]  Samuel Z Goldhaber,et al.  Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study , 2008, The Lancet.

[18]  J. Kahan,et al.  An electronic tool for venous thromboembolism prevention in medical and surgical patients. , 2006, Haematologica.

[19]  S. Iliceto,et al.  Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome , 2010, Journal of thrombosis and haemostasis : JTH.

[20]  A. Turpie,et al.  Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients , 2005, Thrombosis and Haemostasis.

[21]  Lain,et al.  A COMPARISON OF ENOXAPARIN WITH PLACEBO FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS , 2000 .

[22]  E. Vicaut,et al.  Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility , 2010, Annals of Internal Medicine.

[23]  J. Douketis,et al.  The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism , 2007, Annals of Internal Medicine.

[24]  T. Ortel,et al.  Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.

[25]  G. Geroulakos,et al.  Prevention and Treatment of Venous Thromboembolism , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[26]  Jonathan Dreyer,et al.  Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. , 2003, The New England journal of medicine.

[27]  P. Chopard,et al.  Identifying acutely ill medical patients requiring thromboprophylaxis , 2006, Journal of thrombosis and haemostasis : JTH.

[28]  Marilyn D Paterno,et al.  Electronic alerts to prevent venous thromboembolism among hospitalized patients. , 2005, The New England journal of medicine.

[29]  A. Nicolaides,et al.  Prevention and treatment of venous thromboembolism - International Consensus Statement (Guidelines according to scientific evidence) , 2006 .

[30]  P. Prandoni,et al.  Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients , 2008, British journal of haematology.

[31]  L. Melton,et al.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.

[32]  M. Morel-Kopp,et al.  False‐negative or false‐positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant , 2010, Journal of thrombosis and haemostasis : JTH.

[33]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[34]  C. Marosi,et al.  Prediction of venous thromboembolism in cancer patients. , 2010, Blood.

[35]  J. Raffetto Call to action to prevent venous thromboembolism , 2010 .

[36]  J. Heit,et al.  Risk factors for venous thromboembolism. , 2003, Clinics in chest medicine.

[37]  A. Turpie,et al.  Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. , 2007, Chest.

[38]  S. Goldhaber,et al.  New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. , 2000, Chest.

[39]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[40]  Clifford W Colwell,et al.  Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .